As the number of coronavirus cases in the world exceeds 1.4 million, the pharma industry is pushing to find new drugs, therapies and tests in the effort to bring the pandemic under control.
GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into compet
